Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4

Polonini, Hudson; da, Silva Sharlene Loures; Brandão, Marcos Antônio Fernandes; Bauters, Tiene; De, Moerloose Barbara; Ferreira, Anderson de Oliveira

Abstract

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4

Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira

Issue: Nov/Dec 2018 - Volume 22, Number 6

View All Articles in Issue

Page(s): 516-526

Download in electronic PDF format for $75

Abstract

Compounded liquid medication is frequently required in children to allow easy dose adjustment and overcome swallowing difficulties. The objective of this study was to evaluate the stability of oral suspensions compounded with SyrSpend SF PH4 and the commonly used active pharmaceutical ingredients baclofen 2.0 mg/mL, carvedilol 5.0 mg/mL, hydrochlorothiazide 2.0 mg/mL, mercaptopurine 10.0 mg/mL, methadone hydrochloride 10.0 mg/mL, oseltamivir phosphate 6.0 mg/mL, phenobarbital 9.0 mg/mL and 15.0 mg/mL, propranolol hydrochloride 0.5 mg/mL and 5.0 mg/mL, pyrazinamide 100.0 mg/mL, spironolactone 2.0 mg/mL and 2.5 mg/mL, sotalol hydrochloride 5.0 mg/mL, tacrolimus monohydrate 0.5 mg/mL, ursodeoxycholic acid 20.0 mg/mL, and vancomycin hydrochloride 25.0 mg/mL. Suspensions were compounded with raw powders, except for mercaptopurine, pyrazinamide, and sotalol hydrochloride, which were made from commercial tablets. Stability was assessed by measuring the percentage recovery at 0 (baseline), 60 days, and 90 days after compounding for suspensions made with raw powders, which were stored at 2ÅãC to 8ÅãC. The stability of tablets, which were stored at 2ÅãC to 8ÅãC and 20ÅãC to 25ÅãC, was assessed by measuring the percentage recovery at 0 (baseline), 7 days, 14 days, 30 days, 60 days, and 90 days. Active pharmaceutical ingredients quantification was performed by ultraviolet high-performance liquid chromatography via a stability-indicating method. Given the percentage of recovery of the active pharmaceutical ingredients within the suspensions, the beyond-use date of the final products (active pharmaceutical ingredients + vehicle) was at least 90 days for all suspensions in the conditions tested. This suggests that SyrSpend SF PH4 is suitable for compounding active pharmaceutical ingredients from different pharmacological classes.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
May/Jun 2016 Pg. 231	Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm Author(s): Allen Loyd V Jr
Mar/Apr 2024 Pg. 135	Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm Author(s): Allen Loyd V Jr
Nov/Dec 2010 Pg. 512	Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
May/Jun 2017 Pg. 240-241	Updated Stability Data for Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil Author(s): Dijkers Eli, Nanhekhan Valerie, Thorissen Astrid
May/Jun 2020 Pg. 252-262	Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
May/Jun 2005 Pg. 238-241	Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration Author(s): Trissel Lawrence A, Xu Quanyun A
Mar/Apr 2008 Pg. 170-173	Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration Author(s): Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2006 Pg. 144	Sotalol Hydrochloride 5-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Jul/Aug 2006 Pg. 304	Propranolol Hydrochloride 1-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Jan/Feb 2002 Pg. 66-69	Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes Author(s): Xu Quanyun A, Trissel Lawrence A, Pham Lien
Jan/Feb 2002 Pg. 70-73	Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Bupivacaine Hydrochloride Packaged in Plastic Syringes Author(s): Trissel Lawrence A, Xu Quanyun A, Pham Lien
Sep/Oct 2011 Pg. 358-366	Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Author(s): Zur Eyal
Nov/Dec 2012 Pg. 513-515	Stability of Propranolol Hydrochloride in SyrSpend SF Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2013 Pg. 502	Cyclopentolate Hydrochloride 0.2% and Phenylephrine Hydrochloride 1% Ophthalmic Solution Author(s): Allen Loyd V Jr
Jul/Aug 2014 Pg. 330	Propranolol Hydrochloride 1-mg/mL Injection Author(s): Allen Loyd V Jr
Jul/Aug 2018 Pg. 325	Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2015 Pg. 513	Propranolol Hydrochloride Capsules Author(s): Allen Loyd V Jr
May/Jun 2017 Pg. 234	Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base Author(s): Allen Loyd V Jr